Characteristics of the patients (secondary AD case and control groups) treated by autologous HSCT for a primary AD
| Characteristics of the patients treated by autologous HSCT for a primary AD . | Secondary AD cases (n = 29) . | Controls (n = 318) . | P . |
|---|---|---|---|
| Female sex | 21 (72%) | 190 (60%) | .23 |
| Age at diagnosis, y | 20.3 (1.1-55) | 27 (< 1-62) | .17 |
| Age at HSCT, y | 27 (6.7-55.4) | 35.3 (4.2-65) | .04 |
| Interval (mo) from primary AD diagnosis to HSCT | 42.6 (2-179) | 63 (0.4-341) | .06 |
| Year of HSCT | 2002 (1997-2009) | 2002 (1995-2009) | .7 |
| Initial diagnosis, reason for HSCT | |||
| MS | 8 (28%) | 126 (40%) | |
| SSc | 10 (35%) | 94 (30%) | |
| JIA | 4 (14%) | 32 (10%) | |
| SLE | 5 (17%) | 15 (5%) | |
| RA | 1 (3%) | 21 (7%) | |
| Others* | 1 (3%) | 30 (9%) | |
| Conditioning | |||
| Cyclophosphamide | 17 (63%) | 164 (58%) | .27 |
| Fludarabine | 1 (4%) | 1 (< 1%) | |
| Cyclophosphamide/fludarabine | 2 (7%) | 17 (6%) | |
| BEAM | 3 (11%) | 67 (24%) | |
| TBI | 3 (11%) | 25 (9%) | |
| Busulfan | 1 (4%) | 10 (4%) | |
| Serotherapy | |||
| ATG | 26 (90%) | 251 (79%) | .23 |
| Alemtuzumab | 0 | 1 | |
| CD34+ selection | 22 (76%) | 169 (53%) | .04 |
| Stem cell source | |||
| Peripheral blood | 25 (86%) | 293 (92%) | .29 |
| Bone marrow | 4 (14%) | 25 (8%) | |
| Maintenance treatment after HSCT | 9 (31%) | 62 (28%) | .87 |
| Characteristics of the patients treated by autologous HSCT for a primary AD . | Secondary AD cases (n = 29) . | Controls (n = 318) . | P . |
|---|---|---|---|
| Female sex | 21 (72%) | 190 (60%) | .23 |
| Age at diagnosis, y | 20.3 (1.1-55) | 27 (< 1-62) | .17 |
| Age at HSCT, y | 27 (6.7-55.4) | 35.3 (4.2-65) | .04 |
| Interval (mo) from primary AD diagnosis to HSCT | 42.6 (2-179) | 63 (0.4-341) | .06 |
| Year of HSCT | 2002 (1997-2009) | 2002 (1995-2009) | .7 |
| Initial diagnosis, reason for HSCT | |||
| MS | 8 (28%) | 126 (40%) | |
| SSc | 10 (35%) | 94 (30%) | |
| JIA | 4 (14%) | 32 (10%) | |
| SLE | 5 (17%) | 15 (5%) | |
| RA | 1 (3%) | 21 (7%) | |
| Others* | 1 (3%) | 30 (9%) | |
| Conditioning | |||
| Cyclophosphamide | 17 (63%) | 164 (58%) | .27 |
| Fludarabine | 1 (4%) | 1 (< 1%) | |
| Cyclophosphamide/fludarabine | 2 (7%) | 17 (6%) | |
| BEAM | 3 (11%) | 67 (24%) | |
| TBI | 3 (11%) | 25 (9%) | |
| Busulfan | 1 (4%) | 10 (4%) | |
| Serotherapy | |||
| ATG | 26 (90%) | 251 (79%) | .23 |
| Alemtuzumab | 0 | 1 | |
| CD34+ selection | 22 (76%) | 169 (53%) | .04 |
| Stem cell source | |||
| Peripheral blood | 25 (86%) | 293 (92%) | .29 |
| Bone marrow | 4 (14%) | 25 (8%) | |
| Maintenance treatment after HSCT | 9 (31%) | 62 (28%) | .87 |
MS indicates multiple sclerosis; SSc, systemic sclerosis; JIA, juvenile idiopathic arthritis; RA, rheumatoid arthritis; BEAM, BCNU, etoposide, Ara-C, and melphalan; TBI, total body irradiation; ATG, antithymocyte globulin; and y, years.
Others for AD include patients with insulin-dependent diabetes mellitus; others for controls include non-Rheumatoid arthritis, other neurologic diseases, other connective diseases, vasculitis, and hematologic AD.